Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin.

M P Wilhelm1

  • 1Division of Infectious Diseases and Internal Medicine, Mayo, Clinic, Rochester, MN 55905.

Mayo Clinic Proceedings
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Vancomycin effectively treats Gram-positive bacterial infections, including methicillin-resistant staphylococci. Despite rare resistance, it remains a safe and effective antibiotic when monitored properly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated microsporidiosis in a renal transplant recipient: case report and review of the literature.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

Phaeohyphomycosis due to Alternaria species in transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2009
Same author

Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
Same author

Sedimentary nonylphenol contamination in an urbanized, industrialized segment of the Delaware River estuary, USA.

Bulletin of environmental contamination and toxicology·2003
Same author

Fatal disseminated aspergillosis following sequential heart and stem cell transplantation for systemic amyloidosis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2002
Same author

Symposium on antimicrobial agents--Part XII. Vancomycin.

Mayo Clinic proceedings·1999
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Vancomycin is a critical glycopeptide antibiotic for Gram-positive bacterial infections.
  • It is a primary treatment for methicillin-resistant staphylococci and other resistant pathogens.

Purpose of the Study:

  • To review the efficacy and safety of vancomycin.
  • To assess the clinical significance of emerging vancomycin resistance.

Main Methods:

  • Literature review of vancomycin's clinical use.
  • Analysis of reported cases of bacterial resistance to vancomycin.

Main Results:

  • Vancomycin demonstrates bactericidal activity against most target bacteria.
  • Emergence of vancomycin resistance in staphylococci and enterococci is rare.

Related Experiment Videos

  • Serious toxicity is infrequent with therapeutic drug monitoring and controlled infusion.

    • Conclusions:

    • Vancomycin remains a valuable antibiotic for challenging Gram-positive infections.
    • Careful monitoring and administration minimize toxicity risks.
    • Bacterial resistance has not yet become a widespread clinical issue.